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Abstract 
 
During the thesis period a new class of atropisomeric xanthine derivatives has been studied. 
We decided to focus our attention on these purine bases because of their various biological 
activities, that could play an important role in the discovery of new bioactive atropisomers. 
The synthesized compounds bear an Aryl-N chiral axis in position 1 of the xanthine scaffold, 
around which the rotation is prevented by the presence of bulky ortho substituents. Through a 
retro synthetic analysis we synthesized three atropisomeric structures bearing in position 1 of 
the purine scaffold respectively an o-tolyl, o-nitrophenyl and a 1-naphthyl group. The 
conformational studies by DFT simulations showed that the interconversion energy barrier 
between the two available skewed conformations is higher enough to obtain thermally stable 
atropisomers. After the separation of the atropisomers, the experimental energy of 
interconversion was investigated by means of kinetic studies following the thermal 
racemization process using an enantioselective HPLC column. The absolute configuration of 
each atropisomer was assigned by experimental ECD analysis and TD-DFT simulations of the 
ECD spectra. 
Durante il periodo di tesi, è stata studiata una nuova classe di derivati xantinici atropisomerici. 
Abbiamo deciso di rivolgere la nostra attenzione verso queste basi puriniche, a causa delle 
loro note attività biologiche, tali da poter svolgere un ruolo importante nella produzione di 
nuovi composti atropisomerici farmacologicamente attivi. Le strutture sintetizzate non 
appartengono alla classe dei sistemi biarilici, bensì sono caratterizzate da un asse chirale arile-
N in posizione 1 dello scheletro xantinico. La rotazione attorno a tale asse è impedita dalla 
presenza di gruppi arilici orto sostituiti. A seguito di un’analisi retro sintetica, sono state 
sintetizzate tre strutture atropisomeriche recanti rispettivamente un o-tolile, un o-nitro-fenile e 
un gruppo naftile. Gli studi conformazionali effettuati con simulazioni DFT hanno dimostrato 
che la barriera energetica di interconversione tra le due conformazioni enantiomeriche è 
abbastanza alta da poter ottenere atropisomeri stabili a temperatura ambiente. Separati gli 
atropisomeri è stata studiata l' energia sperimentale di interconversione mediante analisi 
cinetiche, monitorando il processo di racemizzazione termica con l’ausilio di una colonna 
HPLC enantioselettiva. La configurazione assoluta di ogni atropisomero è stata assegnata  
tramite simulazioni TD-DFT degli spettri ECD, comparati con gli sperimentali. 
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1. Introduction 
1.1 Axial chirality and atropisomerism 
 
“The universe is asymmetric and I am persuaded that life, as it is known to us, is a direct 
result of the asymmetry of the universe or of its indirect consequences.” (Louis Pasteur, 
L’univers est dissymetrique). 
In 1848, Louis Pasteur recognized the omnipresence and significance of chirality. He realized 
that chiral objects exist as a pair of enantiomorphous mirror images that are non-
superimposable and related to each other, as stated also by Lord Kelvin in 1884, when he 
affirmed “I call any geometrical figure, or group of points, chiral, and say that it has 
chirality, if its image in a plane mirror,  ideally realized, cannot be brought to coincide with 
itself”. 
Today, we know that chirality can be encountered at all levels in nature; it is a key feature of 
natural compounds and plays an essential role in amino acids, peptides and proteins, sugars 
and numerous bioactive substances, including most of the drugs that are used in medicine.  
At the molecular level, chirality gives rise to enantiomers that can exhibit different chemical, 
physical and biological properties in a chiral environment.   
Stereochemistry embraces a broad variety of closely intertwined static and dynamic aspects 
that are all related to the three-dimensional structure of molecules. While static 
stereochemistry deals with the spatial arrangement of atoms in molecules, dynamic 
stereochemistry emphasizes structural change and comprises asymmetric reactions as well as 
interconversion of configurational and conformational isomers. The stereodynamic chemistry 
plays a fundamental role in modern chemistry, from asymmetric synthesis and drug discovery 
to material sciences.1 
Axial chirality is referred to molecules that do not possess a classic stereogenic center, but 
one or more stereogenic axes about which a set of substituents is held in a spatial arrangement 
that is not superimposable on its mirror image. So the presence of axial chirality generates 
different conformers that may be stable at ambient temperature, depending on the rotational 
energy barrier required for racemization of the chiral axis.    
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Bringmann further affirmed the preconditions for axial chirality in his review2, adding that 
three major factors governing the minimum free energy barrier to rotation: (1) the combined 
steric demands of substituents close to the axis; (2) the length and rigidity of bridges (if 
present); and (3) the mechanisms involved in isomerization. 
This source of chirality is called “atropisomerism” (from the Greek,  meaning not and 
 meaning turn), a term proposed by Kuhn in 19333 to describe molecules with a chiral 
axis maintained by hindered rotation about a single bond. This restricted rotation sees the 
origin of compounds with conformational chirality that have enantiomers that can 
interconvert without breaking any covalent bonds, called atropisomers.4 
So, atropisomers are a subclass of conformers that result from slow rotation around a single 
bond due to steric hindrance and/or electronic factors. 
Before the rationalization by Kuhn, atropisomerism was first detected in 6,6’-dinitro-2,2’-
diphenic acid, the enantiomers of which were successfully resolved by Christie and Kenner5 
in 1922.  
In 1983, Oki proposed a boundary between atropisomers and conformers (and therefore 
between configuration and conformation) with his arbitrary definition that atropisomers are 
conformers which interconvert with a half-life t1/2 of at least 1000 s (16.7 min) at +25 °C, 
corresponding to a racemization barrier of 21.8 kcal/mol.6  
Given the absence of a standard stereogenic centre, the absolute configuration of these 
molecules has to be related to the dihedral angle generated by the chiral axis. 
 
Figure 1 Schematic representation of a dihedral angle and its nomenclature. 
In a chain of atoms a-b-c-d (Figure 1), the torsion angle is the dihedral between the plane 
containing the atoms a, b, c and that containing b, c, d (from -180° to +180°) This system has 
two extreme conformations called anti and eclipsed (180 and 0°, respectively). The torsion 
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angle between groups a and d is then considered to be positive (absolute configuration is P or 
∆) if the bond a-b is rotated in a clockwise direction in order to eclipse the bond c-d by 
moving away from the observator. A negative torsion angle requires rotation in the opposite 
sense (absolute configuration is M or Λ).7 
The Cahn-Ingold-Prelog priority rules are applied to the substituents bonded to atoms b and c 
to find atoms a and d and allow the sign of the dihedral angle to be assigned. It is important to 
note that the sign of a dihedral angle remains the same regardless of the side from which it is 
observed, provided that the observation starts from the nearest atom and follows the chain 
toward the farthest. 
The concept of axial chirality as a stereogenic source in a rotationally hindered compound 
was for many years relegated to the academic field. However this situation changed with the 
discovery of many bioactive natural compounds containing stereogenic chiral axes8 and with 
the discovery of many catalysts useful for asymmetric synthesis.2 
The most popular atropisomeric systems used for asymmetric synthesis contain the binaphthyl 
scaffold, where BINAP9 is undoubtedly the most famous example (Figure 2). As pioneered by 
Noyori and his co-workers, Rh complexes of BINAP are useful for the chemoselective 
hydrogenation of C=C and C=O bonds. For the studies in chirally catalysed hydrogenations 
Noyori was awarded the Nobel Prize in Chemistry in 2001.  
 
Figure 2 The two enantiomers of BINAP 
The search for new atropisomeric systems and the related conformational analysis can be 
considered nowadays as an open research field. 
  
PPh2
PPh2
Ph2P
Ph2P
1 (P)-BINAP 1 (M)-BINAP
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1.2 Atropisomerism in drug discovery 
 
The goal for drug discovery is to develop safe and stable substances that specifically target 
essential elements that cause disease. The presence of a source of chirality is an additional 
contribute to the specificity and complexity of a biologically active compound. The inherent 
chirality of biological systems often results in vastly different biological effects of 
enantiomers on the target of interest: classical chiral centre enantiomers have been shown to 
differ significantly in biological activity, pharmacodynamics, pharmacokinetics and toxicity.8b 
The well-known cases of thalidomide10 and perhexiline,11 whose enantiomers led to 
unexpected effects in humans regarding toxicity and metabolic properties, emphasized the 
importance of addressing stereochemistry in drug development. Therefore, it is required by 
regulatory agencies such as the U.S. Food and Drug Administration (FDA) that chiral drugs 
are developed as single enantiomers in cases when this gives improved safety and/or 
efficacy.12 However, there are some drugs for which mixtures of enantiomers have acceptable 
toxicological profiles; if the mixture is not reasonably separable or if racemization is rapid in 
vitro and/or in vivo, it would be futile to administer a single enantiomer (for example 
ibuprofen is sold as a racemic mixture).13 Overall for racemic drug candidates there must be 
an acceptable toxicology and pharmacokinetic profile. In pharmaceutical industry 
stereoisomers are most frequently observed as a result of chiral centers, but atropisomerism 
can be another, yet overlooked, source of drug chirality.   
Anyway the FDA’s statements are referred to classical chiral centered molecules, whereas 
there are no direct guidelines from regulatory agencies on how to deal with atropisomers. 
Atropisomerism may give rise to geometrical isomers, diastereoisomers, or enantiomers, all 
with the feature that they can be thermally equilibrated, involving an intramolecular dynamic 
process that is bond rotation. Moreover, bond rotation is time-dependent and half-life for 
atropisomers can vary between minutes to years, depending on the steric hindrance, electronic 
interactions, temperature and solvent. Because of this time-dependent feature, drug discovery 
campaigns can become more complex. Recently LaPlante, Edwards and co-workers8b gave 
some guidelines to manage this time-dependent feature in the development of atropisomeric 
drugs. The authors suggest to compute the torsion rotational energy barriers to predict the 
existence of atropisomerism along the drug discovery pathway. They have devised a 
classification scheme that helps to understand the features of the drug-like compounds, 
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dividing them in three classes depending on the calculated barrier and rotation rates, as shown 
in Scheme 1: 
 
Scheme 1. Qualitative, cross-discipline guide to help correlate axial (torsion) rotation energy barriers, t1/2, 
and compound classes for predicting development strategies. 
Class 1 compounds possess fast axial rotation rates, in the order of seconds or lower, with 
∆Erot< 20 kcal/mol. They display no axial chirality and are developed as single compounds, 
without any analytical strategy implemented. On the other hand, compounds with ∆Erot> 20 
kcal/mol can generate atropisomers. 
Class 3 compounds have ∆Erot>> 30 kcal/mol, so they have very slow rotation rates, in the 
order of years. These compounds are stable over time and can be isolated as optically pure 
and have an acceptable shelf life. Development can proceed similarly to conventional 
stereoisomers that results from chiral centers. 
Class 2 compounds show axial interconversion with values in the range of minutes, days or 
months. Their development can be challenging, because stereochemical integrity can be 
compromised over the time course of drug production, administration to patients and half-
lives in vivo. In some cases it may be possible to modify the structure to obtain a more 
suitable analogue for development, designing related compounds that have slower or faster 
axial rotation rates. When this is not practical, information on the activity of the separate 
atropisomers in an appropriate in vitro or in vivo model may help support the proposed 
developmental pathway. Information on the rate of equilibration and the equilibrium ratio (for 
atropisomeric diastereoisomers) is valuable for guiding the scientific and regulatory 
discussions in preparation for first-in-human studies. 
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The decision to develop a drug candidate as a purified enantiomer, or a racemate, should be 
made as early as possible during the optimization stage. If possible, options for dealing with 
the atropisomeric phenomenon should be developed and implemented at this early drug 
design stage. 
For example, if the barrier to atropisomerization is high (class 3), one should aim to develop 
the drug as a single, pure and stereochemically stable. This is the case of Telenzepine, a 
selective muscarinic antagonist, that has found use in the treatement of peptic ulcers.14  
 
Figure 3. Slow interconversion between the atropisomers of Telenzepine 2A and 2B 
If the barrier to atropisomerization of a compound is low (class 2), then one should consider 
developing the drug as a consistent and reproducible interconverting mixture.15 This is the 
case for Sch40120 (Figure 4), which is an inhibitor of 5-lipoxygenase. This compound has 
found use in treating acute inflammatory diseases such as psoriasis.16 
 
Figure 4. Compound 3 Sch40120 has a fast racemization, of 1.6 min at +37 °C. The rotation axis is colored 
in red. 
In some cases compounds with atropisomeric interconversion properties can be too 
challenging to be developed as drugs, then for this purpose some practical options can be used 
to simplify the structure. A related approach to simplification is to modulate the rate of axial 
bond rotation through engineering faster bond rotation such as atropisomers no longer exist. 
In this case compounds switch from class 2 to class 1.  
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Foreseeing the existence of atropisomerism in compounds of interest is critical at all stages of 
drug discovery and development. Recently, LaPlante and co-workers showed that a 
computational approach is suitable for this purpose. In this approach, a relaxed torsion scan 
simulates rotation along a sterically hindered bond and the energy is recorded at each 
increment of rotation. The method used is quantum mechanics (QM), for the calculation of 
energy values that consider steric and electronic properties. The computational tool becomes 
useful during the drug discovery pathway, especially when coupled with the classification 
scheme mentioned above in Scheme 1, determining whether to develop the drug as a racemic 
mixture or as an isolated single isomer.  
So, it is apparent that atropisomer chirality could have a significant impact on drug discovery 
and so must be managed appropriately. The first step in dealing with this phenomenon would 
be to recognize its existence for compounds of interest. The QM torsion profile calculations 
are a practical strategy for revealing axial energy barriers to rotation that can result in 
atropisomer properties. Once identified, there are multiple options for dealing with the 
phenomenon of atropisomerism that can be implemented at the early stage of drug design. For 
example, it may be possible to make related analogues with the following features: 1) 
symmetry about a hindered bond, eliminating a chiral axis (making the compound lack 
atropisomer properties); 2) faster rotation about a hindered bond, pushing the half-life for 
conformational interconversion down to the order of seconds; 3) further encumbrance about a 
hindered bond to produce separable atropisomers whose interconversion is negligibly slow 
(bringing the compound to Class 3); or introduction of a stable stereogenic center to perturb 
the population of interconverting atropisomers such that only one desirable conformation 
predominates.8b  
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1.3 Nonbiaryl atropisomers: C-N chiral axis 
 
As mentioned above, over the last two decades there has been a great deal of interest in not 
only the absolute configuration of stable atropisomeric natural products and drugs, due to 
hindered bond rotation, but also in their enantioselective, receptor binding properties. This 
function can be seen as a result of the “adaptability” or “responsiveness” of the 
stereochemistry of atropisomers. And while the vast majority of atropisomers that have been 
studied have been carbocyclic biaryls, these form only one of dozens of conceivable families 
of atropisomers and only during the last 15 years the chemistry of non-biaryl atropisomers has 
moved beyond simple structural observations.  
A number of these non-biaryl atropisomers - diaryl ethers 7, diaryl ureas, anilides 4, 
benzamides 6 and thioamides, styrenes 8 and aryl ketones,  N-aryl carbamates, aryl sulfides 
and sulfones,  N-arylpyrroles 5, indoles and carbazoles among many more – may offer at least 
as many benefits in the fields of biology or catalysis as the biaryls themselves.17 
 
Figure 5 Non-biaryl atropisomers 
Few studies regarding the rotation about the chiral sp2-carbon-nitrogen bond have been 
reported; in fact there are only few examples of anilides, imides, barbiturates and ureas 
derivatives. 
 
Mino, Tanaka and co-workers found that the introduction of two different nitrogen 
substituents to prochiral ortho-substituted anilines and 1-aminonaphtalenes provides aryl 
amines that are axially chiral by virtue of hindered rotation about the aryl-nitrogen bond.18  
In order to minimize steric repulsion between nitrogen substituents and the aryl ring, N,N-
dialkyl arylamines adopt twisted conformations in the ground state.  
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Figure 6 Example of axially chiral arylamines 
The interconvesion of the conformational enantiomers of a series of N,N dialkyl-1-
naphtylamines19 and N-aryl tetrahydropirimidines20 has been studied (figure 6). Notably, 
concurrent nitrogen inversion of these compounds has a very low energy barrier and is only 
observable under cryogenic conditions. This greatly facilitates determination of free energy of 
activation for the rotation about the chiral carbon-nitrogen axis.   
It has been also studied that in order to minimize steric repulsion acetanilides populate a 
conformation in which the aryl ring and the amide group are orthogonal to each other.21 As 
expected the rotation about the axially chiral aryl-nitrogen bond is governed by steric 
interactions between ortho aryl groups and substituents attached to nitrogen atom. In contrast 
to imides, rhodanines and barbiturates the conformational stability of axially chiral ureas is 
significantly lower than that of amides, which is attributed to enhanced ground state strain.22  
 
Figure 7 Example of axially chiral anilides 
The most studied class of biologically active compounds bearing a Caryl-N chiral axis is that of 
barbiturates. Oguz and Dogan studied N-O-aryl substituted barbituric and thiobarbituric acid 
derivatives that are axially chiral due to nonplanar ground states of the molecules.23 The chiral 
axis is the Caryl-Nsp2 bond and all compounds exist as a pair of thermally interconvertable M 
and P enantiomers. The research group determined the energy barriers of these compounds by 
either thermal racemization or temperature dependent NMR. They studied ten different 
structures of barbituric derivatives and they found that oxo-derivatives have a smaller energy 
barrier compared to that of the thioxo-ones. 
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Figure  8 The structure of N-o-aryl substitued barbituric 
The energy barrier for racemization of the o-methyl and o-chloro derivatives were found to be 
similar despite of what happens in different types of N-ortho-aryl substituted heterocyclic 
system, such as arylhydantoins, arylquinolones and aryl-rhodanines, where the chlorine atom 
exerts a greater energy barrier than a methyl group in restricted internal rotation.  
 These results were explained by dipolar repulsion between the exocyclic oxygen and the 
chlorine atom. This repulsion might increase the free energy of the transition state of the 
compound with a chlorine atom as the ortho substituent relative to that of the methyl group as 
the ortho substituent. It can be also argued that the difference in the steric effects of these two 
groups depends on the geometries of the transition states that the two rings assume in passing 
one another. The tetrahedral nature of the methyl substituent may allow, depending on the 
geometry, a lower barrier despite its larger reported van der Waals radius24 than the spherical 
chlorine atom. 
The o-fluoro derivative has the lowest energy barrier (G= 22.2 kcal/mol) cause the smallest 
van der Waals radius of the fluorine atom. On the other hand the naphthyl derivative shows 
the biggest energy barrier (G= 27.7 kcal/mol). 
Pfizer medicinal chemists synthesized one cytokine inhibitor, PH-797804 (13 P), that is of 
particular significance for its excellent kinase selectivity. The PH-797805 (13 M) was much 
less active (figure 9). This atropisomerism arises from restricted rotation caused by the steric 
bulk of the pyridinone carbonyl and 6,6’-methyl substituents on the pyridinone and N-phenyl 
rings. The activation energy of the isomeric interconversion between the P and M isomers 
was predicted to be 31.0 kcal mol–1. Based on the first-order rate equation, the corresponding 
half-life of the two atropisomers is calculated to be about 111 years at room temperature, 
making PH-797804 a clinical candidate with excellent in vitro and in vivo activity. Moreover 
molecular modeling studies indicate that the atropic (P)-isomer readily binds within the active 
site of the kinase. In contrast, the steric clash between the (M)-isomer’s methyl amide moiety 
and the protein’s Asp112 and Asn115 amino acids prevents access to the active site.25 
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Figure 9 The two atropisomers of cytokine inhibitor 
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1.4 Xanthines 
 
Xanthine (3,7-dihydro-purine-2,6-dione), is a purine base. Modified purine bases play an 
important role in biology, and they are interesting systems from biochemical, 
pharmacological, and chemical points of view. In particular, xanthine exists in both 
prokaryote and eukaryote cells and participates in a large variety of functions in most human 
body tissues and fluids.  
A number of central nervous system, muscles and cardiac stimulants26 are derived from 
xanthine, including caffeine27 and theobromine.28  
 
Figure 10  Xanthine derivatives 
Xanthine is an intermediate in nucleic acid degradation from the spontaneous or nitrosative 
deamination of guanine, where the amine group of guanine is substituted by an oxygen atom 
in xanthine. It is also created from hypoxanthine29 by Xanthine Oxidoreductase30 and 
from xanthosine by Purine Nucleoside Phosphorylase (PNP).31,32 Xanthine is subsequently 
converted to uric acid by the action of the Xanthine Oxidase34 enzyme. 
Furthermore, xanthine is a compound present in the ancient solar system. It has recently been 
demonstrated that this purine is one of the original exogenous nucleobases abundant in 
prebiotic age on Earth and may have been one of the precursors for nucleic acids.33  
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1.5 Xanthine derivatives 
 
Xanthine derivatives are a group of alkaloids; many of them are naturally occurring drugs that 
find use as central nervous system stimulants, caffeine being the most famous, one of the 
most widely consumed, biologically active substances.  
1,3-Substituted xanthines constitute an important class of pharmacologically active 
compounds with well-established activities as not only stimulants, but also phosphodiesterase 
inhibitors, which increases cellular cyclic AdenosineMonoPhosphate levels, chloride channel 
activators, and adenosine receptor antagonists. In recent years, the spectrum of clinical 
applications of these xanthines has continued to widen and presently includes their use as 
anticonvulsants  and therapeutics for the treatment of bronchial asthma and vascular 
diseases.34 N3-substituted xanthines, in particular, N3-methylxanthine, an intermediate in the 
metabolism of methylxanthine alkaloids (caffeine, theophylline, and theobromine), possess 
interesting properties such as bronchodilator effects, resulting in relaxation of smooth muscle 
and have been employed to study the dynamics of theophylline-binding RNA aptamers.35 
The most common used xanthine derivative bronchodilator, in fact, is theophylline, a drug 
widely used in the management of asthma. 
In contrast to other, more potent stimulants like sympathomimetic amine,36 xanthines mainly 
act to oppose the actions of the sleepiness-inducing adenosine,37 and increase alertness in 
the central nervous system.38  
All Adenosine Receptor (AR) antagonists are derivatives of the physiological receptor ligand, 
adenosine. The existence of two types of adenosine receptors has been proposed: an A1 
receptor, which mediates inhibition of adenylate cyclase, and an A2 receptor, which 
stimulates the cyclase. Antagonism of either the AI or A2 receptor would permit the selective 
control of the effects caused by the binding of adenosine to that particular receptor.39 The 
most important class of AR antagonists are the xanthines. Numerous xanthine derivatives, 
mainly 1,3-disubstituted (theophylline analogs), 1,3,7-trisubstituted (caffeine analogs), and 
1,3,8-trisubstituted (8-phenyltheophylline analogs), have been synthesized and investigated in 
terms of affinity for A1 and A2 receptors and selectivity.  
Furthermore, the 1-monosubstituted xanthines were more potent at both receptor subtypes 
compared to any other monosubstituted xanthines. So, substitution at the 1-position was 
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necessary for high affinity at adenosine receptors. The 3-monosubstituted xanthines had 
relatively low affinity for ARs. 
 The most potent disubstituted xanthines were the l,3-disubstituted analogs of theophylline, 
particularly at the A1 adenosine receptor. Affinity for AlARs was increased by replacing the 
methyl groups in theophylline by larger substituents from ethyl to propyl and to isobutyl.40 
 
Figure 11 Design of a multivalent dendrimer conjugated to a xanthine. 
Lyles, Cameron and Rawls found also that caffeine (CAF) may be able to reduce the 
cytostatic/cytotoxic activity of DNA intercalators agents that share three common properties: 
(i) they are planar polyaromatic molecules; (ii) they can interact with double-stranded DNA 
(dsDNA) via intercalation; and (iii) they can form non covalent complexes with planar 
polarizing compounds such as CAF. When added simultaneously with or immediately before 
the intercalating agent, CAF has been reported to diminish the cytotoxic effects of the 
hemotherapeutic drugs doxorubicin (DOX) and novantrone in a variety of cell lines. 
Additionally, CAF reduced the cytotoxicity of the DNA intercalator, ethidium bromide, by 
reducing its ability to enter cells. The proposed mechanism responsible for the reduction in 
cytotoxicity by DNA intercalators is the formation of a noncovalent complex between the 
xanthine and the intercalator.41   
In conclusion xanthine and its derivatives had always interested the field of chemistry and 
biochemistry as molecules of study for creating potentially different kind of drugs, thanks to 
their singular biological activities. As a result, the attractive studies on these molecules are 
still in progress; in fact we choose to focus our attention on different atropisomeric xanthines 
derivatives to study in detail this kind of bioactive compounds.  
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2. Results and discussion 
 
During these last decades there has been an increasing interest towards pharmacologically 
bioactive compounds showing atropisomeric features. In particular, the main research goal is 
to synthesize bioactive compounds with conformational chirality due to a rotational energy 
barrier higher than 30 kcal/mol, where the conformers are stable at room temperature with a 
half-life time in the order of years.42 This is a very important feature to reach because the 
pharmacological properties of axially chiral bioactive compounds are directly related to their 
stereodynamic processes.  
The aim of my experimental thesis is the preparation of stable atropisomers of xanthines and 
the resolution of the enantiomeric forms, which could be used in the field of drug discovery.  
To investigate the feasibility of atropisomeric xanthines, three different compounds were 
synthesized following the synthetic scheme reported below: (see Experimental procedure for 
further information) 
 
Figure 22 Synthetic scheme for xanthine derivatives: 24a) Ar = o-tolyl; 24b) Ar = o-nitro phenyl;  
24c) Ar = naphthyl 
Xanthines 25a-c were prepared following literature procedures43 that involve the nucleophilic 
attack of the primary amine to aryl isocyanate giving as intermediate a N-aryl-substituted urea 
that is consequently deprotonated by means of a strong base to achieve the six-membered ring 
closure, leading to the desired purine structure. The final step is the N-3 methylation using 
methyl iodide as methylating agent (figure 22).  
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Scheme 2 Synthetic mechanism to achieve compound 25a-c 
Xanthine scaffold is a planar framework and the ortho-substituted aryl in the 1-position is 
driven out of the xanthine plane because of the steric hindrance caused by the ortho 
substituent. This arrangement implies tilted conformations that generate conformational 
chirality. Depending on the hindrance of the ortho-substituents, the resulting conformational 
enantiomers can be either stereo labile or configurationally stable (atropisomers). Preliminary 
theoretical studies by DFT calculations support indeed the existence of a pair of M and P 
conformational enantiomers, due to the skewed dispositions adopted by the R1,2 substituents 
of aryl-group that can stay up or down the xanthine planar scaffold. 
In figure 13 the two available ground states are reported.   
 
 
 
Figure 13 The two possible enantiomeric  conformations 
GS-P GS-M 
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The interconversion pathway between the two conformational enantiomers can take place 
through two different transition states, depending on the side of the rotation of the R group 
around the Csp2–N chiral axis, through the two different carbonyl moieties (figure 14): 
 
 
Figure 14 Schematic rotation of aryl group about the chiral axis 
TS0 represents the transition of the aryl ortho substituent on the side of the carbonyl group in 
position 2 of xanthine scaffold, while the TS180 the crossing of the same substituent on the 
side of the other carbonyl group in 9 position. Depending on the hindrance of the ortho 
substituent on the aryl group, the transition states may be characterized by different values of 
interconversion energy barrier (∆G≠). A well known approach to analyse the presence of a 
pair of unstable and stable atropisomers is dynamic-NMR spectroscopy. In the present case 
the two conformations are enantiomeric, and their occurrence could be revealed by using a 
CSA (Chiral Solvating Agent), or by the presence of a chirality probe containing two 
germinal moieties that shows diastereotopic signals when conformational enantiomers are 
formed. To avoids the drawback that hampers the use of CSA, we decided to add a chirality 
probe to the xanthine scaffold. To avoid any steric interference with the 1-aryl group, a benzyl 
group was bonded to the nitrogen in position 7 of the xanthine scaffold. This group was 
chosen for the presence of an uncoupled CH2 group that acts as the chirality probe, thus 
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displaying diasterotopic signals (AB system) only when the motion is frozen in NMR 
timescale and a pair of conformational enantiomers has been developed. 
In figure 15 is shown a representation of the effect of the molecular motions on the CH2 NMR 
signal. When the rotation of the aryl group is fast, only a single averaged signal is visible (1H-
NMR spectrum on the top in figure 15). When the rotation of the aryl is slow in the NMR 
timescale (bottom 1H-NMR spectrum in figure 15), the benzyl CH2 act as a chirality sensor 
displaying a double doublet (AB system), due to the different magnetic environment of the 
two diastereotopic hydrogens. 
  
Figure 15 Representation of AB spin system relative to benzyl CH2 at fast and slow rotation. 
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2.1	Stereodynamic: rotational energy barrier 
In the figure below the six synthesized xanthine structures are shown. The 1-aryl-substituents 
are represented by increasingly ortho bulky groups, to achieve the freezing of rotation 
motions. 
 
Figure 16 Atropisomeric xanthine derivatives 
The stereodynamic pathways of each conformer was theoretically modelled by DFT 
optimization performed using Gaussian 09 and the B3LYP/6-31G(d) level of theory, that 
proved to be quite accurate in similar cases. Both ground and transition states were obtained 
(see Appendix for more theoretical details) by full optimization and validated by frequency 
calculation.  
DFT calculations can perform a reliable conformational analysis, useful to predict and 
confirm the relative energies of the ground and transition states, allowing us to choose the 
best experimental approach to study the stereodynamic processes. In addition to that, the 
determination of relative energies among the available transition states gives conformational 
information about the most favourable stereodynamic pathway. The lower value of transition 
state energy, in fact, represents the effective mechanism of interconversion between two 
fundamental states. It is important to stress that only the ground states, and not the transition 
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states, can be experimentally observed, so the effective transition state is deduced only via the 
theoretical simulation. 
Depending on the relative disposition of the benzyl group with respect to the ortho-substituent 
of the 1-aryl ring, two different conformations rise up: they are named syn and anti. The syn 
conformation puts the phenyl ring of the benzyl group on the same side of the ortho 
substituent with respect to the xanthine core, whereas the anti conformation puts the phenyl of 
the benzyl group on the opposite side. A total of four conformations (two pairs of 
diastereoisomer) have therefore to be considered.  
In addition to that, DFT calculations suggested that the N-1-aryl ring is not exactly 
perpendicular to the xanthine scaffold, so two additional conformations have to be considered 
for each syn and anti conformer. The four conformations relative to the M atropisomer are 
shown in figure 17. 
 
Figure 17 Compound 25b: GS-M-syn1, GS-M-syn2 (top), GS-M-anti1, GS-M-anti2 (bottom) 
In table 1 are reported the energy values for both ground and transition state, regarding the M 
enantiomer, derived from DFT calculations. The ground states taken into account are 
clustered into a very small energy range, the highest energy being about 1 kcal/mol above the 
GS-M-syn1 GS-M-syn2 
GS-M-anti1 GS-M-anti2 
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global minimum. The small energy range implies that all the conformations should be 
appreciably populated.  
Table 1 Optimized ground and transition states normalized energies of the atropisomer M, expressed in 
kcal/mol, calculated at B3LYP/6-31G(d) level; the enantiomer P has the same energy values. 
Entry 
GS-M-
syn1 
Da  
(%)b 
GS-M-
syn2 
Da  
(%)b 
GS-M-
anti1 
Da 
(%)b 
GS-M-
anti2 
Da  
(%)b 
TS0-Bn 
up 
TS180-
Bn up 
TS0-Bn 
down 
TS180-Bn 
down 
24a 
0.00 
-79.08° 
(49.8) 
- 
0.00 
-84.47° 
(50.2) 
- 27.58 27.90 27.45 27.94 
24b 
0.00 
-113.08° 
(34.6) 
0.30 
-69.77° 
(20.9) 
0.212 
-105.81° 
(24.2) 
0.317 
-70.25° 
(20.3) 
25.24 24.59 25.15 23.53 
24c 
0.00 
-92.805° 
(53.5) 
- 
0.08 
-91.19° 
(46,5) 
- 30.171 30.471 30.117 30.693 
25a 
0.00 
-79.42° 
(29.4) 
0.169 
-80.46° 
(22.1) 
0.02 
-82.26° 
(28.2) 
0.22 
-97.08° 
(20.3) 
28.08 28.19 27.87 28.27 
25b 
0.00 
-112.59° 
(32.3) 
0.22 
-68.82° 
(22.3) 
0.19 
-104.43° 
(23.5) 
0.23 
-68.75° 
(21.9) 
25.27 23.76 25.12 24.78 
25c 
0.00 
-89.59° 
(52.7) 
- 
0.06 
-91.16° 
(47.3) 
- 30.66 30.74 30.53 31.04 
a Dihedral angle values 
b Percentage of each populated state 
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Compounds 24c and 25c, bearing a naphthyl group, shows only two different ground states, 
because the higher hindrance drives the dihedral angle to 90° (figure 18). 
 
 
Figure 18 Compound 25c: GS-M-syn1, GS-M-anti1 
Conformation GS-syn-1 represents for compounds 25a, 25b, 25c the lowest energy state, 
indicating that the most energetic favourable states is that where the substituted aryl ring is on 
the same side of the phenyl of the benzyl moiety. The most energetically favourable ground 
state of compound 25a is that characterized by the smallest dihedral angle (compound 25a: 
GS-M-syn1= -79.42°); while GS-M-syn1 of compound 25b shows a dihedral angle                 
GS-M-syn1= -112.59°, that is bigger than 90°. 
Depending on the relative disposition of the benzyl moiety (i.e. up or down the planar 
xanthine scaffold) and on the side where the substituted aryl passes during the rotation around 
the chiral axis, four transition states are possible, as shown in figure 19. 
 
GS-M-syn1 GS-M-anti1 
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Figure 19 Transition states of compound 25a, TS0-Bn down is the most stable 
As from table 1, compound 24a, 24c, 25a and 25c prefer the passage on the side of the 
carbonyl in position 2 and with the benzyl group down the xanthine plane, but the energies 
are very close and a reliable conclusion cannot be extracted. On the other hand, the suggested 
energies are rather high, and they should allow for the formation of stable atropisomers. The 
transition states of compounds 24a, 24b, 24c with respect to 25a, 25b, 25c are very close in 
energy, suggesting that there is no influence in the energy barrier when the xanthine core 
bears a N-Methyl group instead of a N-H. While compound 25b, characterized by the o-nitro 
phenyl substituent, shows as energetically favourable the transition state TS180-Bn-up, that 
involves the crossing on the side of the carbonyl in position 9 and the benzyl group up the 
planar scaffold (figure 20). 
TS0-Bn down 
G≠ = 27.87 kcal/mol 
TS0-Bn up 
G≠ = 28.08 kcal/mol 
TS180-Bn up 
G≠ = 28.19 kcal/mol 
TS180-Bn down 
G≠ = 28.27 kcal/mol 
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Figure 20 Most stable transition states of compound 25b 
We found surprisingly a calculated energy barrier lower than the one relative to the compound 
25a for compound 25b, that has a nitro group isosteric with the methyl moiety,44 (23.76 
kcal/mol). The rotation rate of interconversion may be influenced not only by steric 
hindrance, but in this case by electronic factors too. As shown in figure 20 representing the 
TS180-Bn-up, an electronic interaction rises up between the electron-rich oxygen of the 
carbonyl moiety and the electron poor nitrogen of the nitro group. This interaction can 
stabilize the transition state thus lowering the rotational barrier. These theoretical results must 
be supported by the experimental approach, though. 
As from the calculations, all the compounds should feature a G≠ value higher than 25 
kcal/mol, so they should be conformationally stable at ambient temperature. A first test on 
compound 24a was done by using an enantioselective HPLC column (ChiralPak AD-H). The 
chromatogram showed the elution of broadened and closed peaks relative to the two 
enantiomeric conformers. The presence of a secondary free amine group lead often to 
broadened chromatographic peaks, because of its interaction with the stationary phase. 
Although this confirmed the presence of atropisomeric compounds, the peak broadening did 
not allow us a good separation and consequently a good kinetic studies to determine the 
energy barrier.  
To solve this problem we decided to protect the free amine with a methyl group that doesn’t 
interfere with the rotation around the chiral axis, but that allowed us to purify each 
atropisomer without committing any mistakes due to a difficult elution step.  
TS 180- Bn up 
G≠=23.76 kcal/mol 
2 9 
 
25 
Compounds 25a and 25c were purified, using an enantioselective HPLC, by means of 
ChiralPak AD-H column, while the atropisomeric 25b was purified with Lux Cellulose 2 
column (see Experimental section for further details) using different ratio of Hex : iPrOH as 
elution mixtures (table 2). 
Table 2 Elution conditions: compounds 25a and 25c were purified using an enantioselective HPLC by 
means of AD-H column, while 25b was eluted using Cellulose2 column 
Entry 
Elution mixture 
(Hex : iPrOH) (v/v) 
25a 80:20 
25b 50:50 
25c 76:24 
 
Once purified each atropisomer, all the compounds were subjected to kinetic studies at 
different temperatures to obtain the experimental value of the energy barrier of 
interconversion.  
The racemization process, i.e. the thermal equilibration of the two atropisomers was followed 
by means of chiral HPLC (i.e. ChiralPak AD-H column and Lux Cellulose 2 column), with 
the same elution conditions used in the purification step (table 2). 
The kinetic analysis of all the atropisomeric molecules were performed using the same 
experimental approach. An aliquot of a pure enantiomer was dissolved in 1 mL of C2D2Cl4 
using a test tube with screw cap. After that the phial was kept into a bath of DMSO 
surrounded by an oil bath, placed on a hotplate magnetic stirring. The oil bath is necessary to 
keep the temperature controlled by means of a thermocouple put in DMSO solution. The 
choice of C2D2Cl4 was made because its high boiling point that is +146.5 °C, still with a good 
vapor pressure that allows to easily evaporate it. Small samples were taken at different times, 
evaporated the solvent and analyzed by enantioselective HPLC that allowed the determination 
of the enantiomeric ratio.  
Once complete racemization was reached, the experimental values were collected and 
interpolated by a first order reversible kinetic equation and the rate constant (k) values 
referred to each experimental temperature were obtained.  
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Where x is the molar fraction of the enantiomer that is interconverting; xeq is the molar 
fraction of the same enantiomer reached at the equilibrium state (0.5); x0 is the initial molar 
fraction of the chosen enantiomer at t0; k is the rate constant (s
-1); t is the time steps (s). This 
equation represent a straight line in the form y=mx + q, where the slope is (-2k); the y-
intercept is ln (x0-xeq) and t is the independent variable of the function.(see Appendix for 
complete demonstration)  
The resulting k values, not dependent upon concentration, were then used to derive the free 
energy of activation (∆G≠ in kcal/mol) at each temperature by means of the Eyring equation,45 
where T is the absolute temperature and k is the rate constant in s-1: 
∙
	
∆
 
  h = Planck’s constant (1.584·10-34cal·s) 
kB = Boltzmann constant (3.2998·10
-24cal/K) 
R = universal gas constant (1.9872 cal/K·mol) 
κ = transmission coefficient (can be considered equal to 1) 
Solving for ∆G≠ in kcal/mol: 
∆ 4.574	 ∙ 10 ∙ ∙ log 10.318  
Table 3 shows the racemization trend at the temperatures chosen for the kinetic studies of the 
compound 25a (Figure 22).(see Experimental section for the other compounds). 
 
ln (x-xeq) = ln (x0-xeq) -2 k t 
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Figure 21 Example of racemization followed by enantioselective HPLC AD-H of compound 25a at +115°C 
 
Table 3 Compound 25a: Racemization process at each temperature of first eluted atropisomer 
 
 
Figure 22 Compound 25a: Kinetic data fitted with linear regression relative to thermal racemization of 
first eluted atropisomer 
y = -0,00003x - 0,6922
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0 -0,69315 0 -0,69315 0 -0,69315 0 -0,69315 
2520 -0,75184 3420 -0,81058 4620 -0,98967 1800 -0,79186 
4380 -0,82098 6840 -0,92659 8160 -1,212 3600 -0,97657 
9240 -0,96601 10140 -1,05872 11580 -1,42753 6660 -1,32727 
12720 -1,03818 13440 -1,19106 15480 -1,68201 10980 -1,80728 
t=1800 s t=10980 s t=0 s t=3600 s t=6660 s 
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As we can notice from the graphic and table, the experimental values follow a good linear 
trend typical of the kinetic of first order, so they can be reliably interpolated with a linear 
regression to calculate the constant rate values (k).  
Once obtained the k values, the G≠ were calculated through the Eyring equation and the 
results are collected in table 4.  
Table 4 Compound 25a, 25b, 25c: Rate constants and activation energies of interconversion 
COMPOUND 
25a 
T +100 °C T +105 °C T +110 °C T +115 °C 
k (s-1) (x10-5) 1,40 1,87 2,95 5,23 
G≠ (kcal/mol) 30,29 30,49 30,56 30,53 
COMPOUND 
25b 
T +30 °C T +50 °C T +56 °C T +58 °C 
k (s-1) (x10-5) 0,47 4,50 9,67 9,19 
G≠ (kcal/mol) 25,15 25,39 25,38 25,57 
COMPOUND 
25c 
T +100 °C T +110 °C T +120 °C T +130 °C 
k (s-1) (x10-6) 0,79 2,47 6,85 17,74 
G≠ (kcal/mol) 32,42 32,45 32,52 32,60 
Taking into account the errors in the determination of the sample temperature (±1°C), the free 
energies can be considered invariant with the temperature, thus implying a negligible 
activation entropy. This is usual in conformational processes.46 Therefore, the average G≠ is 
carried out to eliminate all the possible experimental errors and these values were compared 
with the calculated. (table 5) 
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Table 5 Experimental and computed energy barriers of rotation around the chiral axis; the calculated 
energies are those of the lowest transition state. 
Entry G≠ exp (kcal/mol) G≠ calc (kcal/mol) t ½ (+25 °C) t ½ (+37 °C)a
 
25a 30.5 28.08 77 years 74 years 
25b 25,4 23.76 5 days 5 days 
25c 32,5 30.53 2353 years 2262 years 
a Normal human body temperature 
We can also observe that the experimental energy value is always in agreement with the 
calculated one, with a difference less than 2 kcal/mol, typical for this kind of DFT calculation.  
So it can lead us to conclude that, as supposed before analyzing DFT optimized conformers, 
the increasingly bulky substituents of the aryl group (methyl and naphthyl moieties) increases 
the rotation about the chiral axis, giving as a result a larger G≠ of interconversion, essential 
for bioactive atropisomeric compounds. Moreover the experimental values of o-nitro phenyl 
substituent does confirm a lower activation energy with respect to the isosteric o-methyl 
phenyl moiety. As speculated above regarding the calculated energy barriers, the activation 
energy of the o-nitro derivative is lowered by the presence of electronic interactions in 
transition state between this group and the two carbonyls of the xanthine planar scaffold.  
From a pharmacological point of view it is very important to take into account the half-life 
time of each atropisomeric compound, that is an essential parameter to consider when a 
bioactive atropisomeric molecule is developed in the field of drug discovery. Therefore we 
have reported the half-life time at room temperature and at +37 °C that is the normal human 
body temperature. 
Applying the reversible first order kinetic equation the half-life time of each compound is: 
t½ = (ln2) / k 
Looking at the energy rotational barrier and half-life time values at room temperature we can 
affirm that compound 25a and 25b belong to the Class 2 of LaPlante classification scheme 
(scheme 1), while 25c is more stable and so is relative to LaPlante’s Class 3 (see Introduction 
for further details).  
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2.2 Absolute configuration 
Once the stereodynamic behavior and thus the conformational stability of each atropisomeric 
structure has been analyzed, the absolute configuration was assigned. The “reference” method 
to assign the absolute configuration relies on the X-ray anomalous scattering (the “Bijvoet 
method”). However, this approach requires the preparation of enantiopure single crystals, and 
the presence of an heavy atom in the molecule  (usually Z>Si when Mo-Kα radiation is used). 
In this case the molecules do not contain any heavy atom, and the assignment by X-ray 
crystallography is unfeasible. 
In the last years the determination of the absolute configuration of chiral molecules using 
chirooptical techniques like optical rotation (OR), electronic circular dichroism (ECD), and 
vibrational circular dichroism (VCD) gained feasibility and reliability because of the 
development of theoretical methods for the prediction of these properties based on DFT and 
on the time-dependent density functional theory approach (TD-DFT).46,47 
In the present case the theoretical calculation of ECD spectra was selected for the absolute 
configuration assignment of all the compounds. The conformational search performed on all 
the atropisomeric structures, showed that 25c has two populated conformations (syn and anti), 
depending on the position of the benzyl compared to that of the naphthyl with respect to the 
xanthine core, whereas compounds 25a and 25b have four ground states conformations for 
each atropisomer (see table 1). 
To compare the calculated ECD spectra to the experimental one, all the populated 
conformations must be considered and their spectra weighted by means of the Boltzmann 
equation, so that the final spectrum takes into account all the contributions. 
The theoretical ECD spectrum of all optimized ground state conformations was obtained with 
the TD-DFT method at CAM-B3LYP48/6-311+G(2d,p) level (see Appendix for further 
details) because this level of theory has been successfully applied to similar cases.49 
The experimental ECD spectra were recorded at +25 °C in acetonitrile solution, using a 
JASCO J-810 spectropolarimeter. The figure below shows both the experimental UV/Vis and 
the ECD spectra of compound 25c.  
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Figure 23 Experimental UV/Vis and ECD spectra of compound 25c 
The ECD spectra calculated for 25c are showed in figure 24, we can notice that the curve is 
characterized by three Cotton effects: one positive that leads to a maximum related to the 
absorption band at 221 nm and two negative which cause the formation of two minima 
respectively at 270 nm and 203 nm. 
The bisignate CD arises because the transition moments of chromophores of the atropisomeric 
compound generate an exciton-coupling. The signs of this curve reflect the chirality between 
the electric transition moments of the interacting chromophores and are ascribable to a 
different absorption of the left and right handed polarized light.  
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Figure 24 Compound 25c: up GS-M-syn and GS-M-anti conformations at the left; ECD calculated spectra 
of GS-M-syn and GS-M-anti at the right. Down ECD calculated spectrum, it is the result of the weighted 
sum of GS-M-syn and GS-M-anti 
An investigation of the molecular orbitals (MO) involved in the UV transitions that generate 
these ECD bands confirmed that the small band centered at 270 nm is mainly generated by 
MOs that involve both the carbonyls of the xanthine scaffold and smaller contributions come 
from MOs involving the naphthyl ring and the benzyl group. The band at higher excitation 
energies centered at 221 nm is due to the electronic transitions that implicate mainly the MOs 
of the naphthyl moiety, but also of the purine scaffold, in particular considering the MOs of 
the five-membered aromatic ring and the CO in position 2 and 9; there is also a smaller 
contribute deriving from the MOs of the phenyl ring. The same happens in the high energy 
band at 203 nm mainly imputable to MOs regarding naphthalene and six-membered ring of 
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xanthine. Also in this case there is a smaller contribution that comes from MOs of the entire 
xanthine moiety and the phenyl ring. 
Table 6 Calculated MOs of compound 25c 
GSM-
syn 
Exc. 
State 
Wavelength 
Oscillator 
strength 
Rotation rate (10-
40 esu2 cm2) 
MO % 
 16 199.52 nm 0.4127 -441.98 
98108 
99106 
98107 
17.65
12.55
11.95
 11 208.74 nm 0.9284 396.38 
98101 
100108 
100107 
39.28
23.06
16.84
 3 259.38 nm 0.1508 -69.05 99102 80.18
GSM-
anti 
Exc. 
State 
Wavelength 
Oscillator 
strength 
Rotation rate (10-
40 esu2 cm2) 
MO % 
 27 191.60 nm 0.0797 62.216 
99107 
99103 
29.29
6.38 
 16 199.64 nm 0.3158 -57.085 
98108 
99105 
97102 
24,50
15,54
5,46 
 15 202.74 nm 0.0830 148.935 
100117 
100118 
37,31
27,69
 11 208.83 nm 1.0852 137.246 
100108 
98101 
45,20
43,62
 3 259.4 nm 0.1450 -21.854 99102 81,89
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Figure 25 Calculated MOs of Compound 25c 
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The most populated MOs involved in the excitation state 3 at 259.4 nm show that the electron 
density is mainly present in the xanthine and naphthyl moieties, as shown in figure 25 for the 
syn and anti conformation. 
The negative 270 nm band is due to the 1La transitions
50 polarized along the short axis of the 
naphthalene chromophore.  
Also in the case of wavelength of 208.74 nm and 208.83 nm, respectively for the syn and anti 
conformers, the most populated MOs involved in the excitation state 11 reveal that the 
electron density is mainly present in the xanthine and naphthyl moieties, as shown in figure 
25 for the syn and anti conformation. 
The positive 221 nm band is due to the 1Bb transitions
6 polarized along the long axis of the 
naphthalene chromophore and the transitions polarized along the long axis of xanthine. 
The dipoles coupling shown in figure below gives the positive dihedral angle P for both the 
anti and syn conformers.  
   
Figure 26 Band at 221 nm is given by the 1Bb transitions along the long axis of naphthalene and the 
transitions on the long axis of xanthine 
The band at 200 nm is the result of the three dipoles of naphthyl, xanthine and benzyl moiety 
and it is more complicated to report schematically.  
Moreover, we have computed the ECD spectra with four different functionals (CAM-B3LYP, 
BH&HLYP, M06-2X, B97XD)49 and all of them give the same bisignate final ECD curve 
P P 
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for the atropisomer M; therefore, comparing the calculated for the M atropisomer and the 
experimental of the second eluted peak, we can affirm that they are completely 
superimposable, leading us to conclude that the second eluted atropisomer has the M absolute 
configuration, while the first eluted peak is characterized by a clockwise dihedral angle about 
the chiral axis and it has P absolute configuration.   
 
Figure 27 Compound 25c up: separation HPLC AD-H column; down: calculated final ECD spectrum of 
the M atropisomer compared to the experimental ECD spectrum of the second eluted enantiomer 
As done for the configurational study for the naphthyl substituted xanthine, we have 
computed the ECD calculated spectra of enantiomer M of compound 25a and 25b. For these 
compounds we have to consider all of the four populated conformers as given by DFT ground 
state calculation (table 1). 
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The figure below shows both the experimental UV/Vis and ECD spectra of compound 25a. 
 
Figure 28 UV/Vis and ECD experimental spectra of compound 25a 
Looking at the simulated ECD spectra for the anti and syn conformations of the M 
atropisomer we found that they exhibit nearly opposite spectra (figure 29 of compound 25a, 
see Experimental procedure for 25b’s ECD spectra). 
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Figure 29 Compound 25a: computed ECD spectra for each populated GS conformations at the top; ECD 
calculated final spectrum at the bottom. 
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Since that the two conformations with different dihedral angle give the same spectra, the 
reasons for the inversion of the spectrum must be searched in the opposite disposition of the 
benzyl group with respect to the ortho substituent of the aryl ring in the two conformations. 
The combination of the two relative dispositions of the dipoles of benzyl produces opposite 
exciton coupling that leads to an inversion of the sign of the spectra depending on the side of 
the benzyl moiety.  
For this reason the final calculated ECD spectrum of each atropisomeric compound is lowered 
because it is obtained by the weighted sum of the opposite contributions of all the possible 
conformations (figure 29). 
To verify the robustness of the final computed ECD spectrum, that must be compared to the 
experimental spectrum to attribute the absolute configuration, we have obtained the simulated 
spectrum by modifying the conformational ratio from 90:10 to 10:90. As demonstrated by 
figure 30 the computed ECD spectrum is effectively robust, in particular we can notice that 
even at 90:10 and 10:90 the inversion of phase of the spectrum doesn’t happen.  
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Figure 30 Calculated ECD spectra of compound 25a with different ratio syn:anti compared to the 
experimentally obtained. 
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The best matching of calculated and experimental data is given by a population ratio of about 
50:50, as suggested by the relative energies calculated by DFT optimization. The 
experimental ECD spectra of 25a and 25b are showed in figure 31. 
 
Figure 31 Experimental ECD spectra of first eluted atropisomer of compound 25a (left) and second eluted 
enantiomer of 25b (right). 
The ECD bisignate curve of compound 25b has a much weaker intensity respect to that of the 
naphthyl substituted xanthine. Also in this case three Cotton effects are present: the first at 
lower energies is positive and leads to a weak  maximum, while the other positive Cotton 
effect characterizes the higher energy band that is a more intense maximum. The only 
negative Cotton effect is attributable to the minimum at 217 nm. Compound 25a, bearing the 
o-tolyl moiety, shows less intense absorption bands, because of the lack of a strong 
cromophore.  
In conclusion, the comparison between the calculated and the experimental spectra leads us to 
attribute the absolute configuration to each atropisomeric structure of compounds 25a and 
25b: the first eluted atropisomer bearing the o-tolyl substituent is the M atropisomer, while 
for compound 25b we can affirm that the ECD calculated spectra for atropisomer M matches 
perfectly with that recorded experimentally for the second eluted peak. It should be noted that 
racemic 25b was resolved on a cellulose-based HPLC column, while 25a was resolved on an 
amilose-based column. The experimental outcomes suggests that the two columns have 
opposite selectivity for these compounds. 
So keeping in mind that the two atropisomers of each xanthine derivative show opposite 
spectrum the table below shows all the absolute configuration attributed: 
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Table 7 Absolute configuration of the three xanthine derivatives 
Entry First eluted enantiomer Second eluted enantiomer Column 
25a M P AD-H 
25b P M Cellulose2 
25c P M AD-H 
 
 
 
44 
2.3 Future goals : diastereoisomeric xanthine derivatives 
 
Since now we have investigated the newly created chiral axis C(sp2)-N in position 1 of 
xanthine scaffold. Given that we have discovered that the naphthyl substituted purine base has 
the highest energy barrier of racemization, showing atropisomers stable at ambient 
temperature for 2353 years, we have decided to start from it to create a new chiral axis C(sp2)-
N in position 3 of the xanthine scaffold. The presence of another chiral axis will allow the 
formation of two diastereomeric pairs of xanthine derivative. 
At first we have tried to investigate some coupling reactions linking to the N-3 a metha 
substituted aryl. Therefore, we focused our attention on the reactions that are shown below : 
 
Figure 32 General synthetic scheme followed for the achieving of xanthine diastereoisomers 
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Table 8 Various reaction conditions for the achieving of xanthine diastereoisomers 
Entry R1 R2 R3 Catalyst Base Solvent Atmosphere Temperature Time Yield 
I B(OH)2 H CH3 Cu(OAc)2
a NEt3 CH2Cl2 O2, 4 Å m.s. r.t.  +40 °C 20 h 80% 
II B(OH)2 H CH3 Cu(OAc)2
 a 
(-) 
Sparteine 
CH2Cl2 O2, 4 Å m.s. r.t. 18 h < 5% 
III B(OH)2 H CH2CH3 Cu(OAc)2
 a NEt3 CH2Cl2 O2, 4 Å m.s. r.t.  +40 °C 20 h 70% 
IV Br H CH3 
Pd(OAc)2
b 
Xantphos 
(Pd/L=1/1.5) 
Cs2CO3 DMF N2 +100 °C 1 h < 5% 
V Br CH3 H 
Pd2(dba)3
c 
Xantphos 
(Pd/L=1/3) 
Cs2CO3 
1,4-
dioxane 
N2 +100 °C. 12 h 0% 
           
VI B(OH)2 NO2 H Cu(Cl)2
d Net3 DMSO O2, 4 Å m.s. +100 °C 14 h 0% 
a The coupling reactions involving Copper as catalyst were conducted with: 1 eq. of 24c, 3 eq. of Boronic acid, 3 eq. of 
Cu(OAc)2, 3 eq. of base. 
bThe coupling reaction involving Palladium as catalyst was conducted with:1.2 eq. of 24c, 1 eq. of Bromide, 10mol% of 
Pd(OAc)2, 1.4 eq. of base.  
cThe coupling reaction involving Palladium as catalyst was conducted with:1 eq. of 24c, 1 eq. of Bromide, 0.005 eq. of 
Pd2(dba)3, 1.4 eq. of base.  
dThe coupling reaction involving Copper as catalyst was conducted with: 1 eq. of 24c, 1 eq. of Boronic acid, 1 eq. of 
CuCl2, 1 eq. of base. 
 
As we can see in the table above, only the first and third reactions gave good results. Both of 
them are characterized by the same synthetic scheme of Chan-Lam coupling. For this reason, 
we decided to follow this reaction scheme coupling an ortho-methyl phenyl moiety to the N 
in position 3, to obtain stable atropisomers, rising the rotational energy barrier values. The 
only change made is the time of reaction that we increase from 20 h to 72 h.   
Unfortunately we haven’t obtained the ortho substituted product with the Chan Lam coupling, 
maybe because of the hindrance of the ortho-aryl boronic acid that during the catalytic cycle 
doesn’t undergoes the reductive elimination step.  
Recently, a new approach regarding the N-arylation of secondary amides has been 
published.51 It allows the introduction of sterically hindered aryl groups under mild 
conditions. The new approach is based on metal-free N-arylation with diaryliodonium salts. 
Few attempts were done with purine 24c and a first good result was obtained. 
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Figure 33 Synthetic scheme followed for the achieving of compound 26a 
Table 9 Different reaction conditions for the synthesis of compound 26a 
Entry Solvent Temperature Yield (%) 
1 Toluene r.t. 0 
2 THF r.t. 0 
3 THF +66 °C 0 
4 DMF +100 °C 
Product 26a: 9 
Product 26b: 12 
 
As shown in table only with DMF the reaction proceeded, giving the desired product 26a.      
The calculated energy barrier for this product is 23.5 kcal/mol, high enough to allow the 
separation of two diastereoisomers. A first separation test using the enantioselective AD-H 
column is shown by the chromatogram in figure 34. It displays the separation of stable 
atropisomers in ratio 22:28, referred to the first and third eluted respectively. The second 
eluted peak is the sum of the two other diastereoisomers. 
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Figure 34 Enantiomeric separation of compound 26a by means of AD-H column 
This could be a good starting point but there is still some way to go to study the 
stereodynamic of these new chiral compounds; first of all there is the necessity of improving 
the synthetic scheme, in order to get a variety of diasteromeric xanthine derivatives in good 
yields. 
t (min) 
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N N
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3. Conclusions 
 
A new class of atropisomeric xanthine derivatives has been studied. We decided to focus our 
attention on these purine bases because of their various biological activities, that could play 
an important role in the discovery of new bioactive atropisomers.  
The synthesized compounds  25a, 25b, 25c are uncommon biaryl systems, but the newly 
created chiral axis in position 1 of the xanthine scaffold is a C(sp2)-N  axis, around which the 
rotation is prevented by the presence of bulky ortho substituents. 
The conformational stability has been predicted by means of DFT simulations yielding a 
rotational energy barrier higher than 25 kcal/mol. 
Through a retro synthetic analysis, we proceeded to the synthesis and characterization of the 
three structures.  
The computed activation energy values were compared to the experimental data that have 
been obtained by means of kinetic studies, following the thermal racemization process with an 
enantioselective HPLC. As expected the increasing of bulkiness of the ortho position of the 
aryl moiety caused a rising of the rotational energy barrier; while, surprisingly, compound 
25b, bearing a o-nitro phenyl group in position 1, showed a lower activation energy respect to 
that characterizing compound 25a that has a o-tolyl substituent. A possible explanation is that 
even if the methyl and nitro group are isosteric, the second develops electronic interactions 
with the carbonyl groups of the xanthine scaffold, thus stabilizing the transition state and 
lowering the energy barrier.  
Once determined the interconversion energy barrier values of all the derivatives, we have 
calculated the half- life time both at ambient temperature and at +37 °C (the normal human 
body temperature), which is an important parameter to consider when a bioactive 
atropisomeric molecule is developed in the field of drug discovery. From these results we can 
affirm that compound 25a and 25b belong to the Class 2 of LaPlante classification scheme, 
while 25c is more stable and can be described as a  LaPlante’s Class 3 compound (compound 
25a: G≠= 30.47 kcal/mol; compound 25b:G≠= 25.37 kcal/mol; compound 25c: G≠= 32.50 
kcal/mol). 
 
 
49 
The absolute configuration was finally assigned using the ECD technique. Compound 25c 
showed an experimental ECD spectrum characterized by intense bands due to the presence of 
exciton coupling between the transition moments of chromophores of the atropisomeric 
molecule. The electronic transitions that generated the CD bisignate curve have been also 
studied by analyzing the  the MOs involved. 
Looking at the simulated ECD spectra of compounds 25a and 25b for the anti and syn 
conformations of the M atropisomer we found that they exhibit nearly opposite spectra. Since 
that the two conformations with different dihedral angle give the same spectra, the 
combination of the two relative dispositions of the dipoles of benzyl produces opposite 
exciton coupling that leads to an inversion of the sign of the spectra depending on the side of 
the benzyl moiety. After verifying the robustness of the final computed ECD spectrum tuning 
the population ratio of syn/anti conformations, we compared the calculated ECD spectrum to 
the experimentally obtained of a pure enantiomeric form.  
From the matching of the two spectra we were able to assign the absolute configuration of 
each atropisomeric structure. 
Table 10 Absolute configuration of the three xanthine derivatives 
Entry First eluted enantiomer Second eluted enantiomer Column 
25a M P AD-H 
25b P M Cellulose2 
25c P M AD-H 
 
Given that we have discovered that the naphthyl substituted purine base has the highest 
energy barrier of racemization, the future goals would be to create diasteromeric xanthine 
derivatives starting from it and making a new C(sp2)-N chiral axis in position 3 of the 
xanthine molecule. We screened some coupling reactions and we found that a metal-free 
coupling, involving iodonium salts can yield the desired compounds.  
It would be also interesting to explore the biological activity of the atropisomeric xanthines 
synthesized because of their potential pharmacological interest. 
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4. Experimental section 
 
4.1 Materials 
Cyanamide, triethyl orthoformate, ethyl 2-bromoacetate and phenylmethanamine were 
commercially available. Cyanamide was purified washing with acetonitrile to eliminate the 
water and then dried. Triethyl orthoformate was distilled before use. THF has been dried 
before use by distillation from Na/benzophenone. The deuterated solvents for NMR spectra 
were commercially available.  
4.2 Instrumentations 
The following stationary phases were employed for the chromatography: Silica gel 60 F254 
(Merck) for the TLC and silica gel 60 Å (230-400 mesh, Sigma Aldrich) for atmospheric 
pressure chromatography.  
Reactions which needed anhydrous conditions were performed under dried nitrogen flow 
(inert atmosphere). The glassware used in these reactions was placed in an oven at +70 °C for 
at least 3 hours immediately before use.  
To purify the products, a HPLC WatersTM 600 instrument with detection fixed at 254 nm was 
used. Phenomenex Luna C18 (5 m 250x21.2 mm, 20 mL/min) semipreparative column was 
used to purify the compounds using mixtures of acetonitrile and water as eluents.  
Enantioselective HPLC columns (DAICEL Chiralcel AD-H 5m 250 × 21.2 mm, 20 mL/min; 
Phenomenex Lux Cellulose-2 5m, 250 x 10 mm, 5mL/min ) have been used to separate the 
stable atropisomers, using different mixtures of hexane and isopropanol as eluent. 
1H-NMR, and 13C-NMR spectra were registered with a Varian Inova 600 MHz and a Varian 
Mercury 400 MHz spectrometer. Chemical shifts are given in ppm relative to the internal 
standards tetramethylsilane (1H and 13C) or relative to the residual peak of the solvents. 
Assignment of the carbons multiplicity were obtained by means of the DEPT sequences. 
ECD spectra were recorded with a JASCO J-810 spectropolarimeter at +25 °C in acetonitrile 
solutions. The concentrations of the samples were tuned to obtain a maximum absorbance of 
about 0.9-1.0 in the UV spectrum, using a quartz cell with 0.2 cm path length.  
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4.3 Calculations 
A conformational search was preliminarily carried out by means of the molecular mechanics 
force field (MMFF), using the package ComputeVOA 0.1.52 The most stable conformers thus 
identified were subsequently energy minimized by DFT computations, which were performed 
by the Gaussian 09, rev. D.01, series of programs using standard optimization parameters.53 
The calculations for ground states and transition states employed the B3LYP hybrid HF-DFT 
method and the 6-31G(d) basis sets. The analysis of the vibrational frequencies for every 
optimized structure has shown the absence of imaginary harmonic frequencies for the ground 
states, and the presence of a single imaginary frequency for the transition states. Visual 
inspection of the corresponding normal mode54 validated the identification of the transition 
states. 
The ECD spectra were simulated by means of TD-DFT calculations. The electronic excitation 
energies and rotational strengths have been calculated in the gas phase using the geometries 
obtained at the B3LYP/6-31G(d) level with the CAM-B3LYP functional. All the calculations 
employed the 6-311++G(2d,p) basis set because this basis set has been widely used in this 
kind of calculation and proved to be sufficiently accurate at a reasonable computational cost. 
The simulated spectra were obtained using the first 60 calculated transitions (lowest 
wavelength about 180 nm) and applying a 0.25 eV line width. The simulated spectra resulting 
from the Boltzmann averaged sum of the conformations were red-shifted by 10 nm to get the 
best simulations with the experimental spectra. 
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4.4 Synthesis 
4.4.1 General  procedure 
Through a retrosynthetic analysis55 the three xanthines were prepared following the general 
synthetic scheme reported below: 
O
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Figure 34 General synthetic procedure 
The two starting reagents were produced from commercially available products using the 
synthetic scheme reported: 
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Figure 35 Synthesis of the two starting compounds 
 
4.4.2 Synthesis of the two starting compounds 
Ethyl 2-(benzylamino)acetate (19):  
 
 
Ethyl 2-bromoacetate (11.09 mL, 0.1 mol) was dissolved in dry THF (100 mL) and the 
solution was cooled in an ice-water bath. Phenylmethanamine (21.84 mL, 0.2 mol) was 
diluted in dry THF (100 mL) and the solution was added to ethyl 2-bromoacetate dropwise. 
After the addition the ice bath was removed, and the reaction mixture was stirred under reflux 
for 2 h under nitrogen atmosphere. This mixture was quenched with an aqueous solution of 
NaOH and extracted with CH2Cl2. The combined organic layer was dried with Na2SO4, 
filtered, concentrated under reduced pressure and purified by fractional distillation under 
vacuum conditions (ethyl 2-(benzylamino)acetate: b.p. +110 °C / 2 mbar. The product was 
obtained as a colorless liquid with a yield of 76% (14.69 g). 
 Spettroscopic data: 
1H-NMR (400 MHz, CDCl3, TMS, +25 °C): δ 1.27 (t, J=7.2 Hz, 3H); 1.87 (s, NH); 3.41 (s, 
2H); 3.81 (s, 2H); 4.20 (q, J=7.2, 2H); 7.26-7.33 (m, 5H). 
13C-NMR (100.6 MHz, CDCl3, 77.0 ppm, +25 °C): δ 14.2 (CH3); 50.1 (CH2); 53.3 (CH2); 
60.7 (CH2); 127.1 (CH); 128.2 (2CH); 128.4 (2CH); 139.5 (Cq); 172.4 (Cq). 
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Ethyl-N-cyanoformimidate (20) 
 
 
Cyanamide (12.73 g, 0.303 mol) was dissolved in triethyl orthoformate (d= 0.891g/mL, 40 
mL, 0.303 mol) and the solution was heated under reflux for 2 h under nitrogen atmosphere, 
then the EtOH was removed by distillation (b.p. +78 °C). Fractional distillation under vacuum 
conditions of the residue gave ethyl N-cyanoformimidate (yield 80%) with b.p. +80 °C / 5 
mbar. Before distilling the desired product we removed the remaining triethyl orthoformate 
and the side-product ethyl formate formed during the reaction by means of distillation (ethyl-
formate b.p. +54°C; triethyl orthoformate b.p. +56 °C/37 mbar). 
Spectroscopic data 
1H-NMR (400 MHz, CDCl3, TMS, +25 °C): δ 1.40 (t, J=7.2 Hz, 3H); 4.39 (q, J=7.2 Hz, 2H); 
8.41 (s, 1H). 
13C-NMR (100.6 MHz, CDCl3, 77 ppm, +25 °C): δ 13.5 (CH3); 65.8 (CH2); 113.6 (Cq); 
171.2 (CH). 
 
 
55 
4.4.3 Synthesis of ethyl 4-amino-1-benzyl-1H-imidazole-5-carboxylate (22) 
 
Two steps synthesis 
First Step (21) 
Ethyl-2-(benzilamino)acetate (3.00 g, 15.52 mmol) in THF (75 mL) was cooled in an ice-
water bath, and ethyl N-cyanoformimidate (1.523 g, 15.52 mmol) in 38 mL of THF was 
added dropwise. The reaction mixture was stirred at room temperature for 4 h.  The mixture 
was concentrated under reduced pressure and was passed through a silica gel plug 
(EtOAc:Hexane = 30:70 with gradient to 100:0) to remove impurities. The intermediate 
appeared as a pale yellow liquid and was obtained with a yield of 97% (3.693 g). 
Second Step (22) 
 t-BuOK (1.742 g, 31.04 mmol) was added to intermediate 21 in 137 mL of THF and the 
reaction mixture was stirred over night at room temperature. The mixture was quenched with 
100 mL of an aqueous solution of NH4Cl and extracted with CH2Cl2. The combined organic 
layer was dried with Na2SO4, filtered, concentrated under reduced pressure and purified by 
column chromatography (EtOAc : Hexane = 2:1 with gradient to 1:0). After recrystallization 
from Et2O, the product was obtained with a 60% yield (2.215 g) as a colorless solid. 
  
 
56 
Spectroscopic data 
COMPOUND 21 
1H-NMR (400 MHz, CDCl3, TMS, +25 °C): E+Z stereoisomers δ 1.23-1.29 (m,6H); 3.92 (s, 
1H); 4.04 (s,1H); 4.17-4.23 (m,4H); 4.58 (s,2H); 4.69 (s,2H); 7.21-7.44 (m, 10H); 8.21 
(s,1H); 8.30 (s, 1H). 
13C-NMR (150.8 MHz, CDCl3, 77 ppm, +25 °C): δ 14.03 (CH3); 14.05 (CH3); 46.0 (CH2); 
49.7 (CH2); 51.4 (CH2); 56.5 (CH2); 61.9 (CH2); 62.2 (CH2); 117.5 (Cq); 117.87 (Cq); 128.2 
(CH); 128.6 (CH); 128.7 (CH); 128.9 (CH); 129.1 (CH); 129.3 (CH); 133.0 (Cq); 133.5 (Cq); 
164.2 (CH); 165.2 (CH); 166.8 (Cq); 167.5 (Cq). 
COMPOUND 22 
1H-NMR (400 MHz, CDCl3, TMS, +25 °C): δ 1.25 (t, J=7.2 Hz, 3H); 4.24 (q, J=7.2 Hz, 2H); 
4.87(NH2); 5.34 (s, 2H); 7.14 (d, J= 6.70 Hz, 2H); 7.23 (s,1H); 7.27-7.35 (m, 3H). 
13C-NMR (150.8 MHz, CDCl3, 77 ppm, +25 °C): δ 14.5 (CH3); 50.7 (CH2); 59.7 (CH2); 
102.0 (Cq); 126.9 (CH); 127.8 (CH); 128.8 (CH); 136.7 (Cq); 139.3 (CH); 161.02 (Cq).  
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4.4.4 Synthesis of 7-benzyl-3-methyl-1-(o-tolyl)-1H-purine-2,6(3H,7H)-dione (25a) 
 
	
 
Two steps synthesis 
First Step (24a) 
o-Tolyl isocyanate (0.05 mL, 0.4 mmol) was added to a solution of 22 (0.050 g, 0.2 mmol) in 
THF (4.7 mL) and the reaction mixture was stirred under reflux conditions for 7h. The 
resulting mixture was concentrated under reduced pressure conditions yielding product 23a. 
DMF and t-BuOK (0.067g, 0.6mmol) were added to 23a. The mixture was stirred under 
reflux overnight. Subsequently, the mixture was quenched with an aqueous solution of HCl 
and extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered, 
concentrated under reduced pressure and purified by column chromatography (EtOAc : 
Hexane = 2:1 with gradient to 1:0) to afford product 24a with a 80% yield (0.053 g).  
Second Step (25a) 
Product 24a was dissolved in THF and t-BuOK (0.036g, 0.32mmol) followed by MeI (d= 
2.28 g/mL, 0.02 mL, 0.32 mmol) were added. The mixture was stirred under reflux conditions 
for 2h and after that, it was extracted with EtOAc. The combined organic layer was dried with 
Na2SO4, filtered and concentrated under reduced pressure to give the compound 25a with 
98% yield (0.054 g). 
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Spectroscopic data 
COMPOUND 24A 
1HNMR (600 MHz, CD3CN, +25 °C): δ 2.07 (s, 3H); 5.46 (s, 2H); 7.15 (d, J=7.8 Hz, 1H); 
7.29-7.38 (m, 8H); 7.85 (s,1H);9.87 (NH).  
13CNMR (150.8 MHz, CD3CN, 1.79 ppm, +25 °C): δ 16.6 (CH3); 49.6 (CH2); 106.9 (Cq); 
126.8 (CH); 127.8 (CH); 128.2 (CH); 128.8 (CH); 128.9 (CH); 129.4 (CH); 130.7 (CH); 
135.3 (Cq); 136.8 (Cq); 136.9 (Cq); 142.5 (CH); 148.4 (Cq); 150.9 (Cq); 155.3(Cq). 
COMPOUND25A 
1HNMR (600 MHz, CD3CN, +25 °C): δ 2.06 (s, 3H); 3.51 (s, 3H); 5.48 (s, 2H); 7.13 (d, 
J=7.8 Hz, 1H); 7.30-7.37 (m, 8H); 7.89 (s,1H).  
13CNMR (150.8 MHz, CD3CN, 1.79 ppm, +25 °C): δ 17.4 (CH3); 30.1 (CH3); 50.6 (CH2); 
107.8 (Cq); 127.6 (CH); 128.7 (CH); 129.1 (CH); 129.5 (CH); 129.7 (CH); 130.2 (CH); 131.5 
(CH); 136.7 (Cq); 137.6 (Cq); 137.8 (Cq); 143.1 (CH); 150.9 (Cq); 152.1 (Cq); 155.6(Cq). 
 
4.4.5 Synthesis of 7-benzyl-3-methyl-1-(2-nitrophenyl)-1H-purine-2,6(3H,7H)-dione 
(25b) 
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Two steps synthesis 
First Step (24b) 
o-Nitro-phenylisocyanate (0.131g, 0.8 mmol) was added to a solution of 22 (0.050 g, 0.2 
mmol) in THF (4.7 mL) and the reaction mixture was stirred under reflux conditions for 7h. 
The resulting mixture was concentrated under reduced pressure conditions and compound 23b 
was obtained. DMF and t-BuOK (0.064g, 0.57mmol) were added to 23b. The mixture was 
stirred under reflux overnight. Subsequently, the mixture was quenched with an aqueous 
solution of HCl and extracted with EtOAc. The combined organic layer was dried with 
Na2SO4, filtered, concentrated under reduced pressure and purified by semipreparative HPLC 
on a Luna C18 column (10 μm, 250 x 21.2 mm, 25 mL/min, ACN:H2O = 63:37 v/v) to afford 
product 24b with a 65% yield (0.047 g). 
Second Step (25b) 
Product 24b was dissolved in THF and t-BuOK (0.028 g, 0.25 mmol) followed by MeI 
(d=2.28 g/mL, 0.016 mL, 0.25 mmol) were added. The mixture was stirred under reflux 
conditions for 2h and after that, it was extracted with EtOAc. The combined organic layer was 
dried with Na2SO4, filtered and concentrated under reduced pressure to give the compound 
25b with 97% yield(0.048 g) 
Spectroscopic data 
COMPOUND 24B 
1H-NMR (600 MHz, CD3CN, +25 °C): δ 5.42 (d, J= 15.2 Hz, 1H); 5.45 (d, J=15.2 Hz, 1H); 
7.32-7.38 (m, 5H); 7.52 (dd, J =7.9, 1.5 Hz, 1H); 7.69 (ddd, J=8.2, 7.6, 1.5 Hz, 1H); 7.84 
(ddd, J=7.9, 7.6, 1.5 Hz, 1H); 7.9 (s, 1H); 8.16 (dd, J=8.2, 1.5 Hz, 1H); 9.52 (NH). 
13C-NMR (150.8 MHz, CD3CN, 1.79 ppm, +25 °C) : δ 50.6 (CH2); 107.6 (Cq); 126.2 (CH); 
128.6 (CH); 129.2 (CH); 129.8 (CH); 130.4 (Cq); 130.9 (CH); 133.2 (CH); 135.4 (CH); 137.5 
(Cq); 144.0 (CH); 147.7 (Cq); 149.6 (Cq); 151.4 (Cq); 155.8 (Cq). 
COMPOUND 25B 
1HNMR (600 MHz, CD3CN,+25 °C): δ 3.52 (s, 3H); 5.45 (d, J= 15.4 Hz, 2H); 5.47 (d, J= 
15.4 Hz, 2H); 7.32-7.38 (m, 5H); 7.49 (dd, J=8.0, 1.4 Hz, 1H); 7.70 (td, J=8.1, 1.4 Hz, 1H); 
7.84(td, J=7.7, 1.5 Hz,1H); 7.93(s,1H); 8.16 (dd, J=8.2, 1.6 Hz, 1H). 
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13CNMR (150.8 MHz, CD3CN,1.79 ppm, +25 °C) : δ 29.2 (CH3); 49.8 (CH2); 106.7 (Cq); 
125.3 (CH); 127.7 (CH); 128.2 (CH); 128.8 (CH); 129.9 (Cq); 130.0 (CH); 132.2 (CH); 134.4 
(CH); 136.5 (Cq); 142.7 (CH); 146.7 (Cq); 150.2 (Cq); 150.9 (Cq); 154.3 (Cq). 
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4.4.6 Synthesis of 7-benzyl-3-methyl-1-(naphthalen-1-yl)-1H-purine-2,6(3H,7H)-dione 
(25c) 
 
 
 
Two steps synthesis 
First Step (24c) 
1-Naphtyl-isocyanate (d= 1.177 g/mL, 0.575 mL, 4 mmol) was added to a solution of 22 
(0.50g, 2mmol) in THF (47mL) and the reaction mixture was stirred under reflux conditions 
for 7h. The resulting mixture was concentrated under reduced pressure conditions and the 
product 23c was obtained. DMF and t-BuOK (0.67 g, 6 mmol) were added to 23c. The 
mixture was stirred under reflux overnight. Subsequently, the mixture was quenched with an 
aqueous solution of HCl and extracted with EtOAc. The combined organic layer was dried 
with Na2SO4, filtered, concentrated under reduced pressure and purified by semipreparative 
HPLC on a Luna C18 column (10 μm, 250 x 21.2 mm, 25 mL/min, ACN:H20 = 90:10 v/v) to 
afford product 24c as a white solid with a 80% yield (0.589 g). 
Second Step (25c) 
Product 24c was dissolved in THF and t-BuOK (0.036 g, 0.32 mmol) followed by MeI 
(d=2.28 g/mL, 0.02 mL, 0.32 mmol) were added. The mixture was stirred under reflux 
conditions for 2h and after that, it was extracted with EtOAc. The combined organic layer was 
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dried with Na2SO4, filtered and concentrated under reduced pressure to give the compound 
25c with 98% yield (0.600 g).  
Spectroscopic data 
COMPOUND 24C 
1H-NMR (600 MHz, CD3CN, +25 °C): δ 5.46 (s, CH2); 7.31-7.38 (m, 5H); 7.45 (d, J=7.4 Hz, 
1H); 7.49-7.51 (m, 1H); 7.55-7.58 (m, 1H); 7.61-7.63 (m, 1H); 7.66 (d, J=8.2 Hz, 1H); 8.01 
(dd, J=8.2, 2.4 Hz, 2H); 9.73 (NH). 
13C-NMR (150.8 MHz, CD3CN, 1.79 ppm, +25 °C) : δ 51.0 (CH2); 108.4 (Cq); 123.6 (CH); 
127.2 (CH); 127.8 (CH); 128.4 (CH); 128.8 (CH); 129.2 (CH); 129.6 (CH); 129.8 (CH); 
130.2 (CH); 130.3 (CH); 132.1 (Cq); 134.3 (Cq); 135.7 (Cq); 138.2 (Cq); 144.0 (CH); 150.0 
(Cq); 152.6 (Cq); 157.2 (Cq). 
 
COMPOUND 25C 
1H-NMR (600 MHz, CD3CN, +25 °C): δ 3.56 (s, CH3); 5.46 (s, CH2); 7.31-7.38 (m, 5H); 
7.45 (d, J=7.4 Hz, 1H); 7.49-7.51 (m, 1H); 7.55-7.58 (m, 1H); 7.61-7.63 (m, 1H); 7.66 (d, 
J=8.2 Hz, 1H); 8.01 (dd, J=8.2, 2.4 Hz, 2H). 
13C-NMR (150.8 MHz, CD3CN, 1.79 ppm, +25 °C) : δ 30.7 (CH3); 51.1 (CH2); 108.5 (Cq); 
123.7 (CH); 127.2 (CH); 127.8 (CH); 128.4 (CH); 128.7 (CH); 129.2 (CH); 129.6 (CH); 
129.8 (CH); 130.2 (CH); 130.3 (CH); 132.1 (Cq); 134.8 (Cq); 135.7 (Cq); 138.2 (Cq); 143.7 
(CH); 151.7 (Cq); 153.1 (Cq); 156.7 (Cq). 
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4.5 Kinetic studies  
 
The experimental values of thermal racemization interpolated with the first order reversible 
kinetic equation of compounds 25b and 25c are reported in table 11 and 12. 
 
Table 11 Compound 25b: Racemization process of first eluted enantiomer at T=+30°C, 
+50°C and +58°C and of second eluted enantiomer at T=+56°C. 
 
T +30 °C T +50 °C T +56°C T +58°C 
t (s) ln(xena1-xena1_eq) t (s) ln(xena1-xena1_eq) t (s) ln(xena2-xena2_eq) t (s) ln(xena1-xena1_eq) 
0 -0,90042 0 -0,73397 0 -0,81803 0 -0,90189 
74700 
 
-1,59554 2280 -0,95946 1680 -1,09602 3540 -1,48281 
97860 -1,81523 5880 -1,25702 5100 -1,77078 7920 -2,29066 
- - 9120 -1,5616 8760 -2,4986 10020 -2,752 
- - 12660 -1,86821 - - - - 
- - 14340 -2,04022 - - - - 
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Figure 35 Compound 25b: Kinetic data fitted with linear regression of first eluted enantiomer at 
T=+30°C,+50°C and +58°C and of second eluted enantiomer at T=+56°C. 
 
Table 12 Compound 25c: Racemization process at each temperature of second eluted 
enantiomer 
y = -0,000009x - 0,9
R² = 1y = -0,00009x - 0,7392
R² = 0,9995
y = -0,0002x - 0,7948
R² = 0,9992
y = -0,0002x - 0,8702
R² = 0,9974‐3
‐2,5
‐2
‐1,5
‐1
‐0,5
0
0 20000 40000 60000 80000 100000 120000
ln
 (
x e
n
a1
-x
en
a1
_e
q
)
t (s)
T 30 °C
T 50 °C
T 56°C
T 58°C
T +100 °C T +110 °C T +120 °C T +130 °C 
t(s) ln(xena2-xena2-eq) t(s) ln(xena2-xena2-eq) t(s) ln(xena2-xena2-eq) t(s) ln(xena2-xena2-eq) 
0 -0,7529 0 -0,7529 0 -0,7546 0 -0,7546 
18720 -0,77653 13860 -0,80386 3900 -0,81622 4860 -0,89575 
79200 -0,85637 22980 -0,86917 8460 -0,93777 9960 -1,07646 
93180 -0,87156 - - 11940 -1,00731 13080 -1,19733 
- - - - 14340 -1,05354 16800 -1,3356 
- - - - 66960 -1,7043 21360 -1,50328 
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Figure 36 Compound 25c: Kinetic data of second eluted enantiomer fitted with linear regression 
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4.6 Absolute configuration 
 
As addressed in Result and discussion the calculated and experimental ECD spectra of 
compound 25b are reported below.  
 
Figure 37 Experimental UV/Vis and ECD spectra of compound 25b 
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Figure 38 Compound 25b: Calculated and experimental ECD spectra the second eluted enantiomer has 
absolute configuration M 
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5. Appendix 
5.1  Density Functional Theory (DFT) 
 
Up to the end of the 1990s, conformational calculations of organic molecules were mainly 
performed by molecular mechanics (e.g., MM3,56 MMX,57 MMFF,58 Amber59 etc.) and 
semiempirical methods (AM1,60 PM3,61 MINDO62 being the most popular). 
The results obtained were often quite accurate, at least for the calculation of the ground-state 
conformations. For the calculation of transition states, in contrast, these methods have 
intrinsic limitations. Usually the interconversion barriers were calculated by moving the 
relative parts of the molecule in fixed steps and optimizing the remaining parts. Otherwise, a 
“handmade” transition state was assumed, and the geometry was optimised within certain 
constraints. As a result of these approximations, the computed barriers were prone to 
relatively large errors, and there was no guarantee that a real transition state had been 
located.63 
When the application of ab initio methods (HF) became available for medium-sized 
molecules the situation was greatly improved, although the neglecting of electron correlation 
was a serious limitation, partially solvable only through the employment of higher methods 
such as MP2.64 Unfortunately, this approach was not manageable without a very large 
computational facility.  
On the contrary, Density Functional Theory (DFT) has the great advantage of taking account 
of electronic correlation at a reasonable computational cost.65 The basic idea of DFT is that 
for a collection of electrons and nuclei the ground state molecular energy, the wavefunction 
and all other molecular electronic properties are uniquely determined by the electron 
probability density ρ(x,y,z), a function of three variables. The ground state energy, E0, is a 
functional of ρ: E0 = F [ρ].
66 
In recent years, the availability of inexpensive high-performance servers and manageable 
software (Gaussian 09,53 and Spartan being the most famous) has allowed high-level 
calculations to be performed in a reasonable amount of time for molecules containing up to 
50–60 atoms. 
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DFT calculations are very interesting because they can be applied both to obtain the 
conformations of ground states and also to find the correct geometries and energies of ground 
and transition states. Thanks to vibrational analysis, there is always confirmation that the 
correct transition state has been unambiguously identified.  
Ground states 
Some uncertainty is involved in determining the relative energies of possible ground states. In 
recent years many papers addressing the performance of various DFT functionals in 
determining relative energies in reactions have appeared,67 but for conformational analysis 
there have been very few. 
For accuracy consideration the smallest basis set used is generally 6-31G* or the equivalent. 
Interestingly, there is only a small increase in accuracy obtained by using very large basis 
sets. This is probably due to the fact that the density functional has limited accuracy  
compared to that of the basis set. The accuracy of results from DFT calculations can be poor 
to fairly good, depending on the choice of basis set and density functional.  
The geometries obtained by calculations can in many cases be checked by X-ray diffraction 
data, and the relative energies of conformations can be compared with the results of kinetic 
studies. Although such a calculation usually refers to an isolated molecule, whereas X-ray 
studies reflect the solid state and kinetic results are for solutions, DFT structures compare 
very well with experimental observations in almost all cases, and the relative energies of 
possible conformations are correctly calculated. 
 
Transition states 
The determination of transition state structures and energies is a crucial point for dynamic 
analysis, because the correct simulation of energy barriers could greatly help the 
understanding of dynamic processes. As addressed by D. Young,68 a transition state (or saddle 
point) structure is mathematically defined as “the geometry that has zero derivative of energy 
with respect to moving every one of the nuclei, and has positive second derivative energy for 
all but one geometric movement”. In other words, a transition state linking two energy minima 
represents a maximum of energy in the direction of the reaction path, but it is a minimum in 
all other directions. 
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Once a stationary point is found, the primary way to verify whether it corresponds to a 
transition state is to compute the vibrational frequencies. A transition state must have only 
one negative (i.e., imaginary) frequency, and the vibrational motion associated with this 
frequency corresponds to the motion going towards reagents in one direction, and towards the 
products in the other. 
Unfortunately, in contrast with the transition states for high-energy processes (such as those 
involved in a chemical reaction), in which the imaginary frequency usually has a large 
(negative) value, the transition states involved in internal dynamic processes usually display 
small negative vibrational frequencies and can therefore be difficult to locate, especially in the 
presence of other possible internal motions. On the other hand, the geometry of a transition 
state is much simpler to idealise, because many geometrical parameters are fixed by the 
molecular scaffold.  
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5.2 Electronic Circular Dichroism (ECD) 
 
The knowledge of absolute configuration is mandatory in many industrial applications. For 
pharmaceutical applications, it is required that the absolute configuration of chiral drugs is 
known and that the biological activity of the compounds is tested for both enantiomers. 
Production of new drugs also requires a verification of the enantiomeric purity of the 
compounds. This leads to the need for characterizing their chiral purity and absolute 
configuration. One widely used method to detect and analyse chirality is the determination of 
the optical activity by circular dichroism (CD).69 In biology, for example, electronic circular 
dichroism (ECD) spectra are frequently used to characterize the secondary structure of 
proteins. 70 
Circular dichroism (CD) is the difference in the absorption of left‐handed circularly polarized 
light (L‐CPL) and right‐handed circularly polarized light (R‐CPL) and occurs when a 
molecule contains one or more chiral chromophores (light‐absorbing groups). Measurements 
carried out in the visible and ultra‐violet region of the electro‐magnetic spectrum monitor 
electronic transitions, and, if the molecule under study contains chiral chromophores then one 
CPL state will be absorbed to a greater extent than the other and the CD signal over the 
corresponding wavelengths will be non‐zero. A circular dichroism signal can be positive or 
negative, depending on whether L‐CPL is absorbed to a greater extent than R‐ CPL (positive 
CD signal) or to a lesser extent (negative CD signal). 
Linearly polarized light is light whose oscillations are confined to a single plane. All 
polarized light states can be described as a sum of two linearly polarized states at right angles 
to each other, usually referenced to the viewer as vertically and horizontally polarized light. 
 
Figure 39 Vertically and horizontally Polarized Light 
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If for instance we take horizontally and vertically polarized light waves of equal amplitude 
that are in phase with each other, the resultant light wave (blue) is linearly polarized at 45 
degrees. 
 
Figure 40 45° Polarized Light 
 
If the two polarization states are out of phase, the resultant wave ceases to be linearly 
polarized. For example, if one of the polarized states is out of phase with the other by a 
quarter‐wave, the resultant will be a helix and is known as circularly polarized light (CPL). 
The helices can be either right‐handed (R‐CPL) or left‐handed (L‐CPL) and are 
non‐superimposable mirror images. 
 
Figure 41 Left Circularly Polarised (LCP) Light Right Circularly Polarised (RCP) Light 
 
The difference in absorbance of left‐hand and right‐hand circularly polarized light is the basis 
of circular dichroism. A molecule that absorbs LCP and RCP differently is optically active, or 
chiral. In fact, whenever a circularly polarized radiation flows through a medium with chiral 
properties, acquires elliptical polarization, whose plane undergoes a rotation. The elliptical 
polarization occurs because the dextrorotatory (ER) and levorotatory (EL) components of the 
electric field vector, constituting the electromagnetic wave, are differently absorbed by an 
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optically active substance: therefore it is necessary to introduce two absorptivity, εR and εL, 
one for each of the two vector components.69,71 
∆ 	 	  
The rotation of plane is due to the different refractive indices, nR and nL, generated from the 
interaction between the component ER and EL respectively, and the chiral substance. The 
result is that the vector components don’t propagate with the same speed but one is more 
accelerated respect the other.  
It is possible to predict the ellipticity (  ) and the angle (  ) of rotation of the plane of a 
polarized radiation, after its interaction with an optically active medium, by means of the 
following equations: 
                                                        
                                                                                                                                   
where  is the wavelength of the monochromatic polarized radiation, and l is the path length 
through the medium chiral . The valuesof  and  are expressed in radians. 
 . 
 
Figure 42 Ellipticity and rotation of the plane of a polarized radiation 
CD may be regarded as one of the most powerful techniques for stereochemical analyses: it is 
sensitive to the absolute configuration as well as to conformational features, which are often 
completely obscured in the ordinary absorption spectrum. 72 
 = (nL-nR)  l

 = (L-R)  l

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The CD of pure enantiomers differs in sign, but not in magnitude. Unfortunately, there is no 
simple relationship between the absolute configuration of an enantiomer and the sign of its 
ECD spectrum: CD depends on details of the electronic and geometric molecular structure.73 
The experimental CD of the molecule under investigation is commonly displayed together 
with either another experimental spectrum, or with the result of a more or less sophisticated 
calculated theoretical curve; in both cases it is very important to correctly choose the 
reference data. An example of experimental and calculated comparison is reported in figure 
43. 
 
Figure 43 Calculated CAM-B3LYP (blue line) and experimental (black line) ECD spectrum of the (S)-2-
Amino-4-(4-chlorophenyl)-6-methyl-4H-chromene-3-carbonitrile 74 
The spectra of two enantiomers of a chiral molecule are conditioned by the chromophores in 
their environment. Every conformational difference, every major alteration in the nature of 
the chromophore or of the perturbing groups between the test and reference makes the 
comparison and determination of absolute configuration unreliable. The appearance of the CD 
spectrum, namely position, intensity and sign of the bands, reflects the environment of each 
chromophore. 
ECD and optical rotation depend sensitively on the presence and nature of solvent 
interactions.75 The change in chiroptical response due to solute–solvent interactions is 
sometimes drastic and non-intuitive. A well-known example is the sign inversion in the 
optical rotation of methyloxirane upon changing the solvent from water to benzene.76  
Classical force-field MD simulations constitute a possible route to explicitly account for 
interactions between molecule and solvent.77 Apart from the high computational cost it might 
appear most desirable to treat the solute embedded in a large number of solvent molecules 
within a first-principles quantum mechanical MD approach. This might only be possible with 
very efficient electronic structure methods such as DFT which on the other hand have 
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deficiencies for non-covalent long-range interactions.78 Time-dependent density functional 
theory (TD-DFT) is presently the most widely used electronic structure method for ECD 
calculations. It extends the basic ideas of ground-state density-functional theory (DFT) to the 
treatment of excitations or more general time-dependent phenomena.  
It turns out that, even with the simplest approximation to the Kohn-Sham potential, spectra 
calculated within this framework are in very good agreement with experimental results.79 
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